JPS6299395A - ２−アルキニルアデノシンおよび抗高血圧剤 - Google Patents

２−アルキニルアデノシンおよび抗高血圧剤

Info

Publication number
JPS6299395A
JPS6299395A JP60240137A JP24013785A JPS6299395A JP S6299395 A JPS6299395 A JP S6299395A JP 60240137 A JP60240137 A JP 60240137A JP 24013785 A JP24013785 A JP 24013785A JP S6299395 A JPS6299395 A JP S6299395A
Authority
JP
Japan
Prior art keywords
blood pressure
formula
compound
effect
antihypertensive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP60240137A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0133477B2 (enExample
Inventor
Sada Miyasaka
宮坂　貞
Akira Matsuda
彰 松田
Toichi Azebiru
藤一 畔蒜
Haruhiko Machida
治彦 町田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamasa Shoyu KK
Original Assignee
Yamasa Shoyu KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamasa Shoyu KK filed Critical Yamasa Shoyu KK
Priority to JP60240137A priority Critical patent/JPS6299395A/ja
Priority to JP15941886A priority patent/JPS6299330A/ja
Priority to CA000521169A priority patent/CA1282065C/en
Priority to DE8686114749T priority patent/DE3683823D1/de
Priority to EP86114749A priority patent/EP0219876B1/en
Priority to AT86114749T priority patent/ATE72448T1/de
Priority to KR1019860008928A priority patent/KR870003782A/ko
Publication of JPS6299395A publication Critical patent/JPS6299395A/ja
Priority to US07/282,892 priority patent/US4956345A/en
Publication of JPH0133477B2 publication Critical patent/JPH0133477B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP60240137A 1985-10-25 1985-10-25 ２−アルキニルアデノシンおよび抗高血圧剤 Granted JPS6299395A (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP60240137A JPS6299395A (ja) 1985-10-25 1985-10-25 ２−アルキニルアデノシンおよび抗高血圧剤
JP15941886A JPS6299330A (ja) 1985-10-25 1986-07-07 抗高血圧剤
CA000521169A CA1282065C (en) 1985-10-25 1986-10-22 Antihypertensive agents comprising 2- alkynyladenosines as active ingredients
DE8686114749T DE3683823D1 (de) 1985-10-25 1986-10-23 2-alkynyladenosine als aktive bestandteile enthaltende antihypertensive mittel.
EP86114749A EP0219876B1 (en) 1985-10-25 1986-10-23 Antihypertensive agents comprising 2-alkynyladenosines as active ingredients
AT86114749T ATE72448T1 (de) 1985-10-25 1986-10-23 2-alkynyladenosine als aktive bestandteile enthaltende antihypertensive mittel.
KR1019860008928A KR870003782A (ko) 1985-10-25 1986-10-24 활성성분으로서 2-알키닐아데노신을 함유하는 항고혈압제
US07/282,892 US4956345A (en) 1985-10-25 1988-12-12 2-alkynyladenosines as antihypertensive agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60240137A JPS6299395A (ja) 1985-10-25 1985-10-25 ２−アルキニルアデノシンおよび抗高血圧剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP15941886A Division JPS6299330A (ja) 1985-10-25 1986-07-07 抗高血圧剤

Publications (2)

Publication Number Publication Date
JPS6299395A true JPS6299395A (ja) 1987-05-08
JPH0133477B2 JPH0133477B2 (enExample) 1989-07-13

Family

ID=17055048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60240137A Granted JPS6299395A (ja) 1985-10-25 1985-10-25 ２−アルキニルアデノシンおよび抗高血圧剤

Country Status (7)

Country Link
US (1) US4956345A (enExample)
EP (1) EP0219876B1 (enExample)
JP (1) JPS6299395A (enExample)
KR (1) KR870003782A (enExample)
AT (1) ATE72448T1 (enExample)
CA (1) CA1282065C (enExample)
DE (1) DE3683823D1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0137786B1 (ko) * 1988-11-15 1998-05-15 하마구찌 미찌오 심장 또는 뇌의 허혈성 질환의 치료, 예방제
KR920700218A (ko) * 1989-06-20 1992-02-19 원본미기재 2-알키닐 아데노신의 합성중간체, 그 합성 중간체의 제조법, 그 합성중간체를 이용한 2-알키닐 아데노신의 제조법 및 안정한 2-알키닐 아데노신 유도체
WO1991009864A1 (fr) * 1990-01-04 1991-07-11 Yamasa Shoyu Kabushiki Kaisha Medicament pour le traitement d'affections ischemiques du c×ur ou du cerveau
GB9014618D0 (en) * 1990-06-30 1990-08-22 Wellcome Found Process for the preparation of pyrimidine nucleosides
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
JP2740362B2 (ja) * 1991-02-12 1998-04-15 ヤマサ醤油株式会社 安定な固体状２‐オクチニルアデノシンおよびその製造法
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
EP0601322A3 (en) * 1992-10-27 1994-10-12 Nippon Zoki Pharmaceutical Co Adenosine deaminase inhibitor.
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US5817641A (en) * 1994-07-21 1998-10-06 Thomas Jefferson University Treatment of enterotoxigenic diarrhea with 2-substituted adenosine derivatives
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
JP3619017B2 (ja) 1998-06-24 2005-02-09 日本臓器製薬株式会社 新規アラビノシルアデニン誘導体
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6593078B1 (en) 1999-04-16 2003-07-15 Schering Corporation Use of azetidinone compounds
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
CA2460911C (en) * 2001-10-01 2011-08-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
WO2003051881A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US7683037B2 (en) * 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
US20050033044A1 (en) 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
SG155182A1 (en) 2004-08-02 2009-09-30 Univ Virginia 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7442687B2 (en) * 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
CN101076343A (zh) * 2004-10-20 2007-11-21 Cv医药有限公司 A2a腺苷受体激动剂的应用
EP1989214B8 (en) 2006-02-03 2016-12-21 Gilead Sciences, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US20080027022A1 (en) * 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
JP2009541354A (ja) * 2006-06-22 2009-11-26 シーブイ・セラピューティクス・インコーポレイテッド 虚血の治療におけるａ２ａアデノシン受容体アゴニストの使用
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
RU2459626C2 (ru) * 2006-09-01 2012-08-27 Гайлид Сайэнсиз, Инк. Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда
WO2008042796A2 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
WO2008086096A2 (en) * 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Myocardial perfusion imaging
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US20110064671A1 (en) 2008-03-10 2011-03-17 Cornell University Modulation of blood brain barrier permeability
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
BR112015002249A2 (pt) 2012-08-01 2017-07-04 Lewis And Clark Pharmaceuticals Inc composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo

Also Published As

Publication number Publication date
KR870003782A (ko) 1987-05-04
CA1282065C (en) 1991-03-26
EP0219876A3 (en) 1988-04-27
EP0219876A2 (en) 1987-04-29
EP0219876B1 (en) 1992-02-05
JPH0133477B2 (enExample) 1989-07-13
DE3683823D1 (de) 1992-03-19
ATE72448T1 (de) 1992-02-15
US4956345A (en) 1990-09-11

Similar Documents

Publication Publication Date Title
JPS6299395A (ja) ２−アルキニルアデノシンおよび抗高血圧剤
US5270304A (en) Therapeutic 2-alkynyl adenosine agent for ischemic diseases of the heart or brain
IL49786A (en) Furo(orthieno)(3,2-c)pyridinium derivatives their preparation and pharmaceutical compositions containing them
JPH024235B2 (enExample)
WO2008061456A1 (en) The folacin-metformin compound and its manufacture
CN111635315B (zh) 一种解热镇痛药物及其制备方法和用途
KR860001865B1 (ko) 2'-데옥시-5-치환 우리딘 유도체의 제조방법
JPS6322082A (ja) １―（ヒドロキシスチリル）―５ｈ―２，３―ベンゾジアゼピン誘導体およびその製造方法、並びに前記誘導体を含む薬剤
JPS6126996B2 (enExample)
JP4548884B2 (ja) ４，５，６，７−テトラヒドロチエノ〔２，３−ｃ〕ピリジン誘導体
JPS6220183B2 (enExample)
JPS6299330A (ja) 抗高血圧剤
JP3025557B2 (ja) ２‐アルキニルアデノシン誘導体
IE54903B1 (en) Long-acting theophylline in medicinal form
JPS6183125A (ja) 癌転移阻害剤
KR20210015940A (ko) 선택성 a2a 수용체 대항제
NO136198B (enExample)
JPH0340039B2 (enExample)
JPH0340036B2 (enExample)
JPS632277B2 (enExample)
JPH0232086A (ja) 新規白金含有化合物および悪性腫瘍治療剤
JPH0340038B2 (enExample)
CN118388421A (zh) 一种姜黄素衍生物及制备方法、应用
JP2774169B2 (ja) 心臓または脳の虚血性疾患の治療・予防剤
JPS59164330A (ja) ポリシルセスキオキサン

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term